ES2076981T3 - Polipeptido fisiologicamente activo y adn. - Google Patents

Polipeptido fisiologicamente activo y adn.

Info

Publication number
ES2076981T3
ES2076981T3 ES90104021T ES90104021T ES2076981T3 ES 2076981 T3 ES2076981 T3 ES 2076981T3 ES 90104021 T ES90104021 T ES 90104021T ES 90104021 T ES90104021 T ES 90104021T ES 2076981 T3 ES2076981 T3 ES 2076981T3
Authority
ES
Spain
Prior art keywords
edema
activity
physiologically active
polypeptide
active polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90104021T
Other languages
English (en)
Other versions
ES2076981T5 (es
Inventor
Tetsuji Sudoh
Keiji Maekawa
Naoto Minamino
Kenji Kangawa
Hisayuki Matsuo
Atsushi Izumi
Mika Takashima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Pure Chemicals Co Ltd
Daiichi Pharmaceutical Co Ltd
Original Assignee
Daiichi Pure Chemicals Co Ltd
Daiichi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26390052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2076981(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from JP04963689A external-priority patent/JP3160276B2/ja
Priority claimed from JP1059183A external-priority patent/JP2883903B2/ja
Application filed by Daiichi Pure Chemicals Co Ltd, Daiichi Pharmaceutical Co Ltd filed Critical Daiichi Pure Chemicals Co Ltd
Publication of ES2076981T3 publication Critical patent/ES2076981T3/es
Application granted granted Critical
Publication of ES2076981T5 publication Critical patent/ES2076981T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE PRESENTA UN POLIPEPTIDO FISIOLOGICAMENTE ACTIVO DERIVADO DEL CEREBRO HUMANO Y UN FRAGMENTO DE DNA QUE COMPRENDE LA SECUENCIA BASE QUE CODIFICA EL POLIPEPTIDO. EL POLIPEPTIDO POSEE UNA ACTIVIDAD DE RELAJACION MUSCULAR EXCELENTE Y SUAVE, ACTIVIDAD DIURETICA O NATRIURETICA, ACTIVIDAD VASODEPRESORA, Y ES UTIL COMO MEDICAMENTO PARA LA CURACION DE ENFERMEDADES CIRCULATORIAS, POR EJEMPLO EDEMA CARDIACO, EDEMA NEFRITICO, EDEMA HEPATICO, EDEMA PULMONAR, HIPERTENSION, FALLO DE CALOR CONGESTIVO, Y FALLO RENAL CRONICO O AGUDO.
ES90104021T 1989-03-01 1990-03-01 Polipeptido fisiologicamente activo y su adn. Expired - Lifetime ES2076981T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP04963689A JP3160276B2 (ja) 1989-03-01 1989-03-01 新規ｃＤＮＡフラグメント
JP1059183A JP2883903B2 (ja) 1989-03-10 1989-03-10 新規生理活性ペプチド及びその用途

Publications (2)

Publication Number Publication Date
ES2076981T3 true ES2076981T3 (es) 1995-11-16
ES2076981T5 ES2076981T5 (es) 2000-02-01

Family

ID=26390052

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90104021T Expired - Lifetime ES2076981T5 (es) 1989-03-01 1990-03-01 Polipeptido fisiologicamente activo y su adn.

Country Status (6)

Country Link
EP (1) EP0385476B2 (es)
AT (1) ATE124994T1 (es)
CL (1) CL2004001266A1 (es)
DE (1) DE69020755T3 (es)
DK (1) DK0385476T4 (es)
ES (1) ES2076981T5 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211686D0 (en) * 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
US5665704A (en) * 1993-11-12 1997-09-09 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5846932A (en) * 1993-11-12 1998-12-08 Genentech, Inc. Receptor specific atrial natriuretic peptides
US6525022B1 (en) 1993-11-12 2003-02-25 Genentech, Inc. Receptor specific atrial natriuretic peptides
US6028055A (en) * 1996-10-22 2000-02-22 Genetech, Inc. Receptor selective BNP
CN1169573C (zh) * 1998-09-28 2004-10-06 参天制药株式会社 用于治疗角结膜障碍的、包含作为活性组分的钠尿肽的泪液分泌促进剂或滴眼剂
PL377813A1 (pl) 2002-11-26 2006-02-20 Biocon Limited Modyfikowane związki natriuretyczne, ich koniugaty oraz zastosowania
US8580746B2 (en) 2006-03-30 2013-11-12 Palatin Technologies, Inc. Amide linkage cyclic natriuretic peptide constructs
WO2007115182A2 (en) 2006-03-30 2007-10-11 Palatin Technologies, Inc. Linear natriuretic peptide constructs
MX2008012663A (es) 2006-03-30 2008-10-13 Palatin Technologies Inc Constructos ciclicos de peptidos natriureticos.
KR20100057063A (ko) * 2007-09-11 2010-05-28 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드의 용도
PL409596A1 (pl) * 2014-09-25 2016-03-29 Uniwersytet Wrocławski Pochodne pseudofaktyny, sposób otrzymywania pochodnych pseudofaktyny oraz ich zastosowanie

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339210C (en) * 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides

Also Published As

Publication number Publication date
DK0385476T4 (da) 1999-12-20
EP0385476B2 (en) 1999-09-22
DE69020755T3 (de) 2000-03-02
DE69020755D1 (de) 1995-08-17
DK0385476T3 (da) 1995-10-02
ES2076981T5 (es) 2000-02-01
EP0385476B1 (en) 1995-07-12
EP0385476A1 (en) 1990-09-05
CL2004001266A1 (es) 2005-02-04
DE69020755T2 (de) 1996-04-04
ATE124994T1 (de) 1995-07-15

Similar Documents

Publication Publication Date Title
ES2076981T3 (es) Polipeptido fisiologicamente activo y adn.
DK163683A (da) Fremstilling af funktionelle humane urokinaseproteiner, dna-sekvens, der koder for et protein omfattende den enzymatiske del af human urokinase, replicerbart udtrykkelsesmedium, der kan udtrykke dna-sekvensen og mikroorganisme eller cellekultur transformeret med mediet
FR2613596B1 (fr) Structure de support de pied, a lanieres en echarpe fixees a la semelle externe d'une chaussure
NO158950C (no) Dna-sekvens som koder for et polypeptid med human fibroblast-interferonaktivitet, fremgangsmaate for dens fremstilling, samt fremgangsmaate for fremstilling av et plasmid.
ES538026A0 (es) Protesis cardiaca total.
DK215287A (da) Dna-sekvenser, der koder for et protein med angiogen virkning, vektorer, vaertsceller og fremgangsmaader til udtrykkelse af proteinet, samt laegemidler indeholdende dette
ATE407949T1 (de) Charakterisierung der proteinfamilie von soc/crac kalziumkanälen
EP0849361A3 (en) Novel ligands of the neuropeptide receptor HFGAN72
DE3787547D1 (de) Verstaerkte, zusammengesetzte struktur.
DE3886175D1 (de) Trigramin, ein Polypeptid, das die Aggregation der Blutplättchen hemmt.
DE3772119D1 (de) Mit kohlenstoffasern verstaerkter kohlenstoffkoerper.
DE69935220D1 (de) Von menschlichem tumor stammendes polypeptidhormon phosphatonin
DK441588A (da) Pulmonaere hydofobe proteiner, associeret med overfladeaktivitet
DE3889640D1 (de) Schuh und Innensohle mit einseitig gerichteter Belüftung.
ATE132900T1 (de) Gene, die ein protein mit menschlicher macif- aktivität kodieren, expressionsvektoren mit diesen genen, transformantenzellen und proteine mit menschlicher macif-aktivität
DE3886517D1 (de) Menschlicher Prourokinase ähnliches Polypeptid.
DE69007065D1 (de) Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten.
MX14312A (es) Procedimiento para la preparacion de un vector de adn recombinante y metodo para la produccion recombinante de una forma zimogena de la proteina c humana.
DE3853743D1 (de) Rekombinanter menschlicher ADF.
WO1999030670A3 (en) Methods of treatment using novel ligands of the neuropeptide receptor hfgan72 and agonists or antagonists thereof
DE68918519D1 (de) DNA, welche für ein antikoagulierendes Polypeptid kodiert.
IT8807016V0 (it) Scarpa con suola zavorrabile per uso sportivo o terapeutico.
DE3779751D1 (de) Schaltung mit verwendung von widerstaenden, welche mittels metallwanderung eingestellt werden.
IT8821003A0 (it) Procedimento per la preparazione del "alfa /4(1,1 dimetiletil)fenil/ 4 (idrossidifenilmetil) 1piperidinbutanolo".
Burnyasheva et al. On the question of the treatment of urticaria

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 385476

Country of ref document: ES